A new report from PitchBook suggests that recent pricing agreements for GLP-1 obesity treatments by Eli Lilly and Novo Nordisk are setting the stage for new competitors to enter the market. The analysis highlights that these pricing plans, coupled with the inclusion of the drugs in Medicare and Medicaid, are expanding the addressable market by an estimated 7 to 15 million people. This expansion and the clearer regulatory pathway are expected to benefit later entrants in the cardiometabolic space. While the current deals are specific to Lilly and Novo Nordisk, they are seen as establishing benchmarks that could lower barriers to entry for other biotech firms developing similar therapies. The report indicates this could reinforce long-term strategies for cardiometabolic franchises.